Abstract
Available evidence demonstrates that the DNA repair machinery is involved in melanoma resistance to chemotherapeutics. Furhtermore, preclinical findings suggest that interfering with DNA repair could increase chemosensitivity of melanoma cells. However, the clinical implementation of these principles is still in its infancy and no such strategy is currently proven to be effective in patients with advanced melanoma. Since the molecular mechanisms governing the relationship between chemoresistance and DNA repair are not fully elucidated, more basic and translational research is needed to understand the reasons for the failures and to identify novel targets. In this review we summarize the experimental and clinical findings that are fostering the research in this promising field of oncology.
Keywords: Melanoma, DNA repair, chemotherapy, chemoresistance, demonstrates, preclinical findings, chemosensitivity, clinical implementation, novel targets, oncology
Current Medicinal Chemistry
Title:Circumventing Melanoma Chemoresistance by Targeting DNA Repair
Volume: 19 Issue: 23
Author(s): S. Mocellin, L Bertazza, C. Benna and P. Pilati
Affiliation:
Keywords: Melanoma, DNA repair, chemotherapy, chemoresistance, demonstrates, preclinical findings, chemosensitivity, clinical implementation, novel targets, oncology
Abstract: Available evidence demonstrates that the DNA repair machinery is involved in melanoma resistance to chemotherapeutics. Furhtermore, preclinical findings suggest that interfering with DNA repair could increase chemosensitivity of melanoma cells. However, the clinical implementation of these principles is still in its infancy and no such strategy is currently proven to be effective in patients with advanced melanoma. Since the molecular mechanisms governing the relationship between chemoresistance and DNA repair are not fully elucidated, more basic and translational research is needed to understand the reasons for the failures and to identify novel targets. In this review we summarize the experimental and clinical findings that are fostering the research in this promising field of oncology.
Export Options
About this article
Cite this article as:
Mocellin S., Bertazza L, Benna C. and Pilati P., Circumventing Melanoma Chemoresistance by Targeting DNA Repair, Current Medicinal Chemistry 2012; 19 (23) . https://dx.doi.org/10.2174/092986712802002509
DOI https://dx.doi.org/10.2174/092986712802002509 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting the EGFR-family for Therapy: Biological Challenges and Clinical Perspective
Current Pharmaceutical Design Quinone Methides as DNA Alkylating Agents: An Overview on Efficient Activation Protocols for Enhanced Target Selectivity
Current Organic Chemistry A Curcumin Analog, GO-Y078, Effectively Inhibits Angiogenesis through Actin Disorganization
Anti-Cancer Agents in Medicinal Chemistry Novel Drugs for Chronic Lymphoid Leukemias: Mechanism of Action and Therapeutic Activity
Current Medicinal Chemistry Comparison of the Inhibitory Effects of Clotrimazole and Ketoconazole against Human Carboxylesterase 2
Current Drug Metabolism Next Generation Sequencing in the Management of Leptomeningeal Metastases of Non-Small Cell Lung Cancer: A Case Report and Literature Review
Recent Patents on Anti-Cancer Drug Discovery A Review of the Recent Developments in Synthetic Anti-Breast Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry The Potential for Genetically Altered Microglia to Influence Glioma Treatment
CNS & Neurological Disorders - Drug Targets Targeting Trail Towards the Clinic
Current Drug Targets Computer Aided Drug Design Approaches for Identification of Novel Autotaxin (ATX) Inhibitors
Current Medicinal Chemistry MicroRNA Key to Angiogenesis Regulation: MiRNA Biology and Therapy
Current Cancer Drug Targets Molecular Biological Roles of Ursolic Acid in the Treatment of Human Diseases
Current Bioactive Compounds Enhancing Transdermal Drug Delivery with Electroporation
Recent Patents on Drug Delivery & Formulation STAT3 Regulation of Glioblastoma Pathogenesis
Current Molecular Medicine Editorial (Thematic Issue: Immunophilins, Protein Chemistry and Cell Biology of a Promising New Class of Drug Targets – Part II)
Current Molecular Pharmacology Technetium Labeled Small Peptide Radiopharmaceuticals in the Identification of Lung Cancer
Current Pharmaceutical Design The Role of Notch Signaling Pathway in Epithelial-Mesenchymal Transition (EMT) During Development and Tumor Aggressiveness
Current Drug Targets Novel HSP90 Inhibitor NVP-AUY922 Enhances the Anti-tumor Effect of Temsirolimus Against Oral Squamous Cell Carcinoma
Current Cancer Drug Targets SPARC in Tumor Pathophysiology and as a Potential Therapeutic Target
Current Pharmaceutical Design Current Advances in L-DOPA and DOPA-Peptidomimetics: Chemistry, Applications and Biological Activity
Current Medicinal Chemistry